X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DIVIS LABORATORIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DIVIS LABORATORIES AUROBINDO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 18.2 18.8 97.1% View Chart
P/BV x 5.9 4.1 145.7% View Chart
Dividend Yield % 0.4 1.5 23.0%  

Financials

 AUROBINDO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
AUROBINDO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,5412,484 62.0%   
Low Rs582918 63.4%   
Sales per share (Unadj.) Rs237.5142.3 166.9%  
Earnings per share (Unadj.) Rs33.941.9 80.9%  
Cash flow per share (Unadj.) Rs40.646.3 87.6%  
Dividends per share (Unadj.) Rs2.5010.00 25.0%  
Dividend yield (eoy) %0.20.6 40.1%  
Book value per share (Unadj.) Rs120.6161.5 74.7%  
Shares outstanding (eoy) m585.17265.47 220.4%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.512.0 37.4%   
Avg P/E ratio x31.340.6 77.2%  
P/CF ratio (eoy) x26.236.7 71.2%  
Price / Book Value ratio x8.810.5 83.6%  
Dividend payout %7.423.9 30.9%   
Avg Mkt Cap Rs m621,041451,525 137.5%   
No. of employees `00013.33.7 358.4%   
Total wages/salary Rs m15,5083,649 425.0%   
Avg. sales/employee Rs Th10,457.610,184.4 102.7%   
Avg. wages/employee Rs Th1,167.1984.1 118.6%   
Avg. net profit/employee Rs Th1,491.62,998.5 49.7%   
INCOME DATA
Net Sales Rs m138,96137,764 368.0%  
Other income Rs m1,663848 196.0%   
Total revenues Rs m140,62438,612 364.2%   
Gross profit Rs m32,05614,138 226.7%  
Depreciation Rs m3,9261,182 332.2%   
Interest Rs m2,56823 11,067.2%   
Profit before tax Rs m27,22513,781 197.6%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,4442,662 279.6%   
Profit after tax Rs m19,82011,119 178.3%  
Gross profit margin %23.137.4 61.6%  
Effective tax rate %27.319.3 141.5%   
Net profit margin %14.329.4 48.4%  
BALANCE SHEET DATA
Current assets Rs m100,01530,947 323.2%   
Current liabilities Rs m74,7595,195 1,439.1%   
Net working cap to sales %18.268.2 26.7%  
Current ratio x1.36.0 22.5%  
Inventory Days Days107117 92.0%  
Debtors Days Days11085 128.7%  
Net fixed assets Rs m52,35017,027 307.5%   
Share capital Rs m585531 110.2%   
"Free" reserves Rs m67,70742,341 159.9%   
Net worth Rs m70,56742,877 164.6%   
Long term debt Rs m8,4725 180,255.3%   
Total assets Rs m156,99449,684 316.0%  
Interest coverage x11.6595.0 2.0%   
Debt to equity ratio x0.10 109,523.9%  
Sales to assets ratio x0.90.8 116.5%   
Return on assets %14.322.4 63.6%  
Return on equity %28.125.9 108.3%  
Return on capital %37.732.2 117.2%  
Exports to sales %51.085.3 59.9%   
Imports to sales %18.822.9 82.3%   
Exports (fob) Rs m70,92732,198 220.3%   
Imports (cif) Rs m26,1938,654 302.7%   
Fx inflow Rs m71,01532,270 220.1%   
Fx outflow Rs m28,7998,775 328.2%   
Net fx Rs m42,21623,496 179.7%   
CASH FLOW
From Operations Rs m17,59610,379 169.5%  
From Investments Rs m-13,801-4,135 333.8%  
From Financial Activity Rs m-198-6,241 3.2%  
Net Cashflow Rs m3,5973 108,993.9%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.8 67.4%  
FIIs % 27.7 19.0 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.2 59.3%  
Shareholders   69,601 31,796 218.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Pharma Drug Approvals, Global Updates, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS